Xcellerex announces successful production of swine flu H1 Hemagglutinin

Xcellerex officials announced this week that they have successfully produced swine flu H1 Hemagglutinin, California strain.

Xcellerex founder and chief technology officer Parrish Galliher told Business Wire the strain was created in 42 days, “beginning from the amino acid sequence of the protein.”

Galliher noted that during that time period, “the gene was cloned and expressed, fermentation and purification processes developed, and the quality product shown to be fully within the specifications set out by the Defense Threat Reduction Agency under its Accelerated Manufacturing of Pharmaceuticals contract.”

The tests came on the heels of  a two-year, $19 million contract funded by Defense Advanced Research Projects Agency and the Defense Threat Reduction Agency’s Transformational Medical Technologies Initiative. Those contracts were part of a government effort to support development of technology to combat biosecurity threats and pandemics.

The endeavor was a joint effort between Xcellerx, Pfenex Inc., deltaDot Ltd. and BioPharm Services, according to the report.

“We are very pleased with the results of the test, which demonstrated the performance of rapid, flexible, and portable biomanufacturing,” Galliher said. “The results exceeded our expectations and we thank Pfenex, deltaDOT and BioPharm Services for their teamwork to achieve these outstanding results.”

Charles Squires, vice president of discovery and external partnerships at Pfenex Inc., agreed.

“The successful execution of the test brings to conclusion an extraordinary multi-year effort put forth by all the participants on the team,” Squires said. “The team was able to bring together cutting edge protein expression, production and analytical technologies with state of the art process modeling software to deliver a vaccine antigen with unprecedented speed, quality and cost.”